FILTER
FILTERED INTERVIEW RESULTS
Tim J. Swendseid
CEO, ELEVATION GOLD MINING
"This year, as a result of our efficiency improvements and mine plan optimizations, we expect to produce between 34,000 to 36,000 oz Au."
Steve Trussell
EXECUTIVE DIRECTOR, ARIZONA MINING ASSOCIATION
"Demand for materials is rising exponentially with emerging technology and clean energy solutions. There is tremendous pressure on supply. Where these materials are mined and refined is going to matter from a strategic, safety, environmental and economic standpoint."
Óscar González Rocha
CEO, ASARCO
"When compared to other Grupo Mexico operations in Peru and Mexico, Asarco in US has been affected by cost implications stemming from labor availability concerns."
Steve Tallant
SENIOR DIRECTOR, SOLUTION MARKETING GROUP AT SYSTECH, A SOLUTIONS DIVISION OF MARKEM-IMAJE
"We are taking a physical supply chain and creating a digital twin of products and data moving through the chain."
Tim Tyson
CHAIRMAN AND CEO, TRIRX PHARMACEUTICAL SERVICES
"Our focus on capacity utilization, market demand, and strategic acquisitions will be key drivers of TriRx's growth in the coming year."
Trevor Caswell
CHAIRMAN, PHARMA.AERO
"Pharma.Aero is a unique collaborative platform connecting life sciences shippers and service providers to achieve reliable end-to-end air transport for pharmaceutical cargo."
Denise Juliano
GROUP VICE PRESIDENT, LIFE SCIENCES, PREMIER INC.
"Our technology and data capabilities help researchers and providers gain insights into health inequities and support strategies and solutions to advance health equity."
Cory Lewis
CEO, PRESIDENT AND CO-FOUNDER, INCOG BIOPHARMA SERVICES
"Wrapping up Q1 in 2023 we are now above 80 employees with a facility that is cGMP production ready and actively manufacturing commercial PPQ batches for one of our biopharma clients."
Aaron Montgomery
PRESIDENT AND CEO, OURAY
"Among our customers, we note a heightened awareness of preventative safety practices. Also, OURAY see a lot of growth in those exceedingly hazardous chemicals such as fluoridated and brominated materials."
Katrin Rupalla
CEO, YMMUNOBIO
"Based on our in vivo data for our lead CEACAM1/5 antibody YB-200, we have obtained orphan drug status from FDA for the treatment of liver cancer."
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
USA Mining 2025-26 - Pre-release
USA Mining 2025-26 pre-release is a snapshot capturing insights from over 70 executives and decision-makers across the value chain and from coast to coast, sharing not only how the industry is changing, but also where it is heading next.
USA Mining 2025-26 pre-release is a snapshot capturing insights from over 70 executives and decision-makers across the value chain and from coast to coast, sharing not only how the industry is changing, but also where it is heading next.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
